News | May 28, 2024
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Launch of 20 new medicines expected by 2030
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
US FDA approval based on NEURO-TTRansform Phase III results
Development services for gene and cell therapies is planned to begin first in 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
